Mercer Global Advisors’s Candel Therapeutics CADL Stock Holding History
Bought
Maintained
Sold
Other funds holding CADL
ACA
SVCM
Mercer Global Advisors's CADL Position: Q3 2026 in Review
Mercer Global Advisors increased its Candel Therapeutics (CADL) stake by 5.3% in Q3 2026, buying an estimated $28.9K and bringing the position to 51,765 shares worth $540K. The position accounts for ﹤0.01% of the portfolio, ranked #2386.
Mercer Global Advisors first reported a position in CADL in Q2 2026 and has held it in 2 quarters since. 141 funds tracked by Wall St. Rank hold CADL as of Q3 2026.
- Mercer Global Advisors held 51,765 shares of Candel Therapeutics worth $540K as of Q3 2026.
- Mercer Global Advisors bought 2,611 Candel Therapeutics shares in Q3 2026, an estimated $28.9K.
- Candel Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q3 2026, its #2386 holding.
- Mercer Global Advisors first reported a position in Candel Therapeutics in Q2 2026 and has held it in 2 quarters since.
- 141 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.
Based on Mercer Global Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.